using a reversed-phase column (100 μm, ID × 15 cm, Reprosil-Pur 120 C18-AQ, 1.9 µm, Dr. Math). The mobile phases were H2O with 0.1% FA and 2% ACN (phase A) and 80% ACN and 0.1% FA (phase B). Separation of the sample was executed with a 120-min gradient at a 300 nL/min flow rate. Gradient B was as follows: 8-35% for 92 min, 35-45% for 20 min, 45-100% for 2 min, 100% for 2 min, 100-2% for 2 min and 2% for 2 min. Data-dependent acquisition was performed in the profile and positive mode with the Orbitrap analyzer at a resolution of 70,000 (200 m/z) and m/z range of 350-1400 for MS1; for MS2, the resolution was set to 17,500 (200 m/z). The automatic gain control (AGC) target was set to 1.0e+06 for MS1 and 1.0e+05 for MS2. The top 10 most intense ions were fragmented by higher energy collisional dissociation (HCD) with a normalized collision energy (NCE) of 28% and isolation window of 2 m/z. The dynamic exclusion time window was 30 s.
MaxQuant database search
Raw MS files were processed with MaxQuant (Version 1.5.6.0). The human protein sequence database (Uniprot_HUMAN_2016_09) was downloaded from UNIPROT.
This database and its reverse decoy were then compared by MaxQuant software. The quantification type was MS1; trypsin was set as the specific enzyme with up to 2 misscleavages; oxidation [M] and acetyl [protein N-term] were considered as variable modifications, whereas carbamidomethyl [C] was set as a fixed modification; and both peptide and protein FDR should be less than 0.01. Only unmodified unique peptides were used for quantification. iBAQ label-free quantification was also performed with log fit checked.
Figure legend
Supplemental information includes 13 figures and 4 tables. Supplementary Table 1 Primers, oligos, shRNA, siRNA and sgRNA used in the experiment.
Supplementary Tables

Supplementary Table 2
The clinical characteristics of retinoblastoma patient cohorts.
Supplementary Table 3
The clinical characteristics of neuroblastoma patients.
Supplementary Table 4
The list of lncRNA GAU1 binding proteins. Supplementary Figure 1 CCK8 assay was performed to measure proliferative rate after GAU1 or GALNT8 overexpression in normal cells. (D) A colony formation assay was performed to assess normal cell (ARPE19 and RPE1) growth with GAU1 and GALNT8 over-expressing.
Supplementary Figures
Quantification of visible colonies. The colony number of the pcDNA3.1 group was set to 1. (E, F) A CCK8 assay was performed to assess normal cell (ARPE19 and RPE1) growth with GAU1 and GALNT8 over-expressing. All the experiments were performed in triplicate, and the relative colony formation rates are shown as mean ± SEM. *p < 0.05. pcDNA3.1: negative control group transfected with empty pcDNA3.1 vector. 
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